Published in Haematologica on January 22, 2012
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood (2013) 1.64
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol (2013) 1.06
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol (2013) 0.98
Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer. Curr Hematol Malig Rep (2016) 0.85
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood (2015) 0.84
Ethical and clinical aspects of intensive care unit admission in patients with hematological malignancies: guidelines of the ethics commission of the French society of hematology. Adv Hematol (2014) 0.78
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk (2016) 0.77
Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy. Haematologica (2016) 0.75
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol (2017) 0.75
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy. Haematologica (2017) 0.75
Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents. Haematologica (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2010) 9.77
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol (2009) 5.86
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol (2010) 4.21
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol (2009) 3.07
The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer (2008) 2.91
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol (2009) 2.78
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood (2011) 2.52
Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol (2006) 2.22
Non-compliance with oral chemotherapy in childhood leukaemia. BMJ (1996) 2.02
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood (2009) 2.00
Compliance of pediatric and adolescent cancer patients. Cancer (1986) 1.97
The effects of imatinib on pregnancy outcome. Blood (2008) 1.92
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood (2004) 1.76
Adolescent and young adult oncology: an emerging field. J Clin Oncol (2010) 1.75
Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics (2005) 1.39
Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol (2010) 1.36
Role of palliative care in adolescent and young adult oncology. J Clin Oncol (2010) 1.33
Malignant hematologic diseases in adolescents and young adults. Blood (2011) 1.32
Treatment compliance in childhood and adolescence. Cancer (1993) 1.31
Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther (1988) 1.24
Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. J Pediatr (1992) 1.23
Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2010) 1.20
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood (2011) 1.19
Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program (2010) 1.14
Sex, drugs, and rock 'n' roll: caring for adolescents and young adults with cancer. J Clin Oncol (2010) 1.09
Clinical pharmacology in the adolescent oncology patient. J Clin Oncol (2010) 1.08
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer (2003) 1.06
Research challenges in adolescent and young adult cancer survivor research. Cancer (2011) 1.06
The cancer is over, now what?: Understanding risk, changing outcomes. Cancer (2011) 1.00
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol (2008) 0.99
Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer (2010) 0.98
Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. Eur J Haematol (2008) 0.96
Adherence issues in pediatric bone marrow transplantation. J Pediatr Psychol (1990) 0.94
Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med (2010) 0.90
Lack of progress in teen and young adult cancers concerns researchers, prompts study. J Natl Cancer Inst (2006) 0.89
Proceedings of a workshop: bridging the gap in care and addressing participation in clinical trials. Cancer (2006) 0.87
Profile of non-compliance in lymphoblastic leukaemia. Arch Dis Child (1997) 0.86
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res (2010) 0.85
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia (1996) 0.83
Psychological correlates of compliance. Am J Pediatr Hematol Oncol (1983) 0.83
Cooperation with treatment in adolescent cancer patients. J Adolesc Health Care (1986) 0.81
Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer (2004) 0.81
Caregivers' perceptions of medical compliance in adolescents with cancer. J Adolesc Health Care (1986) 0.80
Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med (1996) 0.77
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2010) 9.77
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest (2010) 4.70
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood (2010) 4.51
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell (2010) 4.07
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2003) 4.07
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw (2008) 3.82
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer (2008) 3.75
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood (2002) 3.46
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood (2007) 3.29
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer (2007) 3.28
Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med (2015) 3.25
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15
Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer (2007) 3.10